Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emerging drug Zactima from AstraZeneca will earn 4.7 percent patient share in the treatment of non-small-cell lung cancer (NSCLC) by 2016. Surveyed oncologists indicate that they would prescribe Zactima to 30 percent of their patients with advanced non-small-cell lung cancer. Also, 38 percent of the physicians surveyed indicate they will use Zactima as an adjunct to current therapy rather than as a replacement. Zactima is forecasted to launch in 2008 in the United States and Europe and in 2010 in Japan.
According to the new report entitled Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious; physicians indicate that the most promising emerging therapies for the treatment of non-small-cell lung cancer will not match the current gold- standard regimen comprising Roche/Genentech/Chugai's Avastin, Bristol-Myers Squibb's Taxol, and Bristol-Myers Squibb's Paraplatin.
"Although some therapies in development for advanced NSCLC hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with the Avastin/Taxol/Paraplatin regimen," said Andrew Merron, Ph.D., analyst at Decision Resources. "A therapy's effect on overall survival is the attribute that most influences prescribing decisions in advanced non-small-cell lung cancer. Data and the opinions of interviewed thought leaders indicate that Avastin/Taxol/Paraplatin has advantages over the sales-leading combination of Sanofi-Aventis's Taxotere and Bristol-Myers Squibb's Platinol-AQ on overall survival."
About the Report
Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy Continues to Be Most Efficacious is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/